The authors describ e a prospective p ilot study design ed to investigat e the use oftop ical nasal antifungal spray in addition tosys temic steroids anditracona zole in the treatment ofallerg icfu ngal sinusitis. Sixteenpatients with a history of allerg icfungal sinusitis weregivenfluconazole nasal spray andfo llowed fo r 3 nionths. Stabilizati on or improvement ofdisease without significant side ejJects was observed in J2 ofthe J6 p atients who were treated with this protocol. These results indi cat e that topicalflu conazole app lication may help patients with all ergic fungal sinusitis; ltowe vet; a larg er multicenter study with longer patient fo llow-up is required to validate these initialfindings.
Introduction
AlIergic fungal sinu sitis (AFS) is a form ofchronic sinu sit is characterized by nasal obstruction, sinus pain , rhinorrhea, and frequent orbital symptoms. Computed tomography (CT) frequ entl y shows unilateral involv em ent with areas of hyperd ensity in the affected sinuses . Histol ogicall y, fungal hyphae are not seen in all patient s, and ther e is usu ally ev ide nce of bony eros ion of the sinus walls. Extensive eos inophilic infiltrate may be seen with maj or basic protein (MBP) in the mucosal site of dis eas e. Conve ntiona l treatm ent con sists of sinus surgery with extirp ation of the allergic mucus, fo llowe d by postoperative ventilation of the sinuses and the use of sys tem ic steroids. Frequent saline nasal irrigati on has been used to cle ar the nasal and sinus cavit y. Desp ite all of these interventions, AFS has a high rate of recurrenc e. From Fungal sinusitis pre sent s in five major form s, each of which requires a differ ent approach to treatment and has a different progno sis bas ed on the extent of disease.Acute fulminant invasive fung al sinusitis is com mon ly seen in an immunocompromised host. This dise ase is clinically aggr essive, destroying tissue and bon e. Histopathologically, the fungu s is angioinva sive and cau ses widespread necrosis. Treatm ent is aggressive surgic aI debridement and the use of antifunga l drug s. If the underlying immunocompromi sed state is not corr ected, the prognosis is significantly worse.':'
Chronic invasive fung al sinusitis occur s mainly in diabetic patients, causing a chr onic low-gr ade inflamm atory reacti on, as weil as tissue necrosis. Ag gressive surg ical debridem ent and antifungal drugs are again the treatments of choice. How ever, this disease commonly recurs and has a pcor prognosis.'' Granulomatous invasive fungal sinusitis occurs in an immunocompetent hostand is usuall yunilateral. Theorganism is invasive but limit ed to the superfi cial mucosa and weil cont ained within surrounding granulomas. Surgery fo1lowed by antifun gal dru gs is usually the treatment ofchoice, and the progno sis is sati sfactory in most pati ents .':'
Fungal ball OI' sinus mycetoma occurs in a unil ateral sinus in an immunocompetent host. Histologically, there is no evidence of tissue invasion OI' granulomatous inflammation. Surgical removal is the treatm ent of choice, and patients usually have an uneventful recovery.!" AFS was first described by Millal' et al in 1981, when they reported 5 patients with significa nt Type I hypersensitivity to Aspergillus and sinus pathology similar to pulmonary findin gs in patient s with allergic bronchopulmon ary aspergillosis (A BPA)." Th ese pati ents present with asthma, incr eased total serum immunoglobulin E (IgE), pulm onary eosi nophilia, specific allergic immune response, and thick, tenaciou s mucus that cause s bronchial obstructi on and bronchiectasis. In 1983, Kat zenstein et al reviewed 113con secuti ve histop athologic specimens from chronic sinusitis surge ries and identifi ed 7 cases ofallergic aspergillus sinusitis.i 'Ihey described this as allergic mucin, 
Mucosal Atomization Device
whieh eonsisted ofdegenerating eosinophils, desquamated respiratory epithelial eel1s, and Charcot-Leyden crystals. Fungal stains revealed fungal hyp hae but no evidenee of tissue invasion. Subsequent ease reports deseribed identieal findings with other fungi, and the disease was termed al1ergie fungal sinusitis. '
The five major eriteria for AFS are evidenee of IgEmediated hypersensitivity, nasal polyposis, eharaeteristie CTfindings, eosinophilie mueus, and positive fungal smear or cu lture. The minor eriteria include asthma, unilateral predominanee, radiographie bone erosion, funga l culture, Chareot-Leyden crystals, and serumeosinopbilia.t-vTreatment co ns ists of surgery fol1owed by postoperative ora l corticosteroids.? Conventional treatment consists of ethmoideetomy and middle meatal antrostomywith removal of the al1ergie mueus fol1owed by postoperative ora l corticosteroids. Systemie antifungals have not proved eonsistently benefieial beeause the fungi are noninvasive.s?
The goal of this study was to evaluate the ro le of a topiea l antifungal spray in the treatment of AFS .
M aterial and methods
This prospeetive study was based at a tert iary teaehing hospita!. Using an open enrol lment, patients with a history ofAFS were se leeted beeause ofprogression ofsymptoms during treatment, Partieipants were advised of the non-FDA -approved use of an FDA -approved drug and given the option to withdraw from the study .
Sixteen patients with a history of AFS were given flueonazole nasal sprayand fol1owed for 3 months (table) . Of the 16 patients who partieipated in the study, 8 were men and 8 were women . Their ages ranged from 39 to 74 years. Previous treatment ineluded systemie itraeonazole alone in 5 patients and systemie itraeonazole and oral prednisone in 8 patients. Three patients did not have any previous treatment,
The flueonazole us ed in the study was form ulated by SinuCare, Inc . (AItamonte Springs, Fia.) . It eonsisted of 100 mg of flueonazo le in 500 mi of normal sa line so lution administered as 5 sprays (0.5 ee/spray) in eaeh nostril twice dai ly.
Patients were fol1owed monthly with nasaI endoseopy, and their response to treatment was assessed through the serial nasa I endoseopie examinations eomparing the presenee of polyps and mueosal edema. The patients' symptoms and their pereeption of response to treatment also were reeorded.
Results
Twelve of the 16 patients (75%) had stab le disease or a deerease in mueosal edema during treatment wit h the antifungal nasal spray; 4 patients (25%) had progression of the edema during treatment with the nasal spray.
Three patients (19%) had po lyps prior to starting treatment; their polyps did not regress with treatmerit. Thirteen patients showed no evidenee of polyps prior to starting treatrnent. Ten patients eontinued to be free of polyps during treatment; however, 3 patients developed polyps during treatment.
Subjeetively, 12 patients (75%) pereeived no worsening or improvement in their symptoms with treatment, The other 4 patients felt their symptoms were worse during treatment, Three patients were treated with the nasal sprayonly. Two showed improvement or were stable; one did not respond to treatment. 
Discussion
Th e initial treatm ent of AFS is surgical debulking of the affe cted sinuses and removal ofallergic mu cin and reactive hypertrophied or hype rplast ic mucosa. Both the fungu s and the diseased mu cos a are removed , and the obst ruc ted sinuses are revent ilated .v ? Waxm an et al suggested the use of systemic cort icosteroids postop eratively, based on the treatment mod aliti es used in A BPA. l1 Th ey look ed at 26 patien ts, 10 of wh om rece ived postop erat ive steraids, and noticed that the patient s give n stera ids had less dis ease on follo w-up endos copic exami nation. Kuhn and Javer followed Il pati ent s with A FS wh o were give n systemic steraids postoperatively and notic ed a signifi cant decrease in muc os aI disease.? Incomplete surg ica l removal of the pathol ogic tissue usually rend ers the patien t susceptible to relaps e of the disease.v -'-Antifungal drug s give n systemically have not pra ved effec tive for treatm ent ofAFS , prim arily becau se the dru gs are not secreted into the nasal secretion. Th e fun gu s is not invasive; and because the dru gs are not secreted into the mucus, fun gicidal level s are not ac hieved in the mu cous linin g of the nasal cav ity and the paranasal sinuses .v" [n th is study, topi eal antifunga ls were studied as the only intervention or in combination w ith sys temic antifunga ls and sys temic steraids. [n AFS, tissue damage is no t ca use d by invasive fun gu s but rath er by the immunologic hyperreaction ass oci ated w ith the presen ce of a funga l antigen in an atopic individua1. 2 ,3,9,12-1 4Applicati on oftopica l antifunga ls should achieve fun gicid al conc entrations in the nasal and paranasal sinus muc osa, erad icatin g the fung us and thu s reducing funga l antige n load .
Most of the pati ent s in thi s study had stable sympto ms with application of the top ieal antifunga l spra y. We interpreted this as success of the antifunga l spray, becau se the maj ority of patient s in thi s treatm ent regim en had no progression ofthe disease. How ever, relap ses inAFS have been show n to occur as mu ch as 2 yea rs after treatment.
Thi s study followed [ 6 pati ent s for only 3 months, The next step wo uld be to add a placebo group, utilize a stand ard qu ality-o f-l ife qu estionnaire, and fo llow the patient s longer.
Conclusion
AFS is a difficult disea se to treat, because pat ient s ofte n experi enc e multiple relap ses, Th e main stay of treatm ent is surg ica l deb ridem ent follow ed by syste mic sterai ds . Systemic anti fun gals have not pra ved effective ; ho wever, based on th e preliminary findin gs in this study, there may be a ra ie for topi eal antifunga ls. Fu rther investigati on is warr ant ed,
